Advertisement

Intraperitoneal chromic phosphate in peritoneoscopically confirmed Stage I ovarian adenocarcinoma

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      From December 15, 1975 to June 16, 1980, 20 evaluable patients with International Federation of Gynaecology and Obstetrics Stage I invasive adenocarcinoma of the ovary were entered into a prospective study, including pretherapy restaging peritoneoscopy followed by treatment with intraperitoneal chromic phosphate if there was no evidence of residual macroscopic tumor. During a follow-up of 1½ to 6 years (median, 3 years and 1 month), the survival rate without evidence of recurrent ovarian carcinoma was 95%. Moreover, there was a total absence of complications with the use of the sequential steps of pretherapy peritoneoscopy, a normal preinjection peritoneogram, injection of chromic phosphate in large volumes of solution, frequent change of position of the patient after injection, and abdominal scans after injection. This method appears to be safe and is associated with a significantly high survival rate.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leichner P.K.
        • Cash S.A.
        • Back X.C.
        • Duran R.E.
        Effects of injection volume on the tissue dose, dose rate, and therapeutic potential of intraperitoneal P32.
        Radiology. 1981; 1401: 193
        • Fuks A.
        The role of radiation therapy in the management of ovarian carcinoma.
        Isr. J. Med. Sci. 1975; 13: 815
        • Piver M.S.
        • Barlow J.J.
        • Lele S.B.
        Incidence of subclinical metastasis in Stage I and II ovarian carcinoma.
        Obstet. Gynecol. 1978; 52: 100
        • Keettel W.C.
        • Fox M.R.
        • Longnecker D.S.
        • Latourett H.B.
        Prophylactic use of radioactive gold in the treatment of primary ovarian cancer.
        Am. J. Obstet. Gynecol. 1966; 94: 766
        • Roesenshein N.B.
        • Blake D.
        • McIntyre P.A.
        The effect of volume on the distribution of substances instilled into the peritoneal cavity.
        Gynecol. Oncol. 1978; 6: 106
        • Piver M.S.
        Radioactive colloids in the treatment of Stage I ovarian cancer.
        Obstet. Gynecol. 1972; 40: 42
        • Currie J.L.
        • Bagne F.
        • Harris C.
        • Sullivan D.L.
        • Surwit E.A.
        • Wilkinson R.H.
        • Creasman W.T.
        Radioactive chromic phosphate suspension: Studies on distribution, drug absorption, and effective therapeutic radiation in phantoms, dogs, and patients.
        Gynecol. Oncol. 1981; 12: 193